NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Forecast, Price & News $7.06 -0.51 (-6.74%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$7.01▼$7.8150-Day Range$3.72▼$8.0852-Week Range$2.91▼$8.39Volume316,193 shsAverage Volume1.56 million shsMarket Capitalization$807.59 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Mersana Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.5% Upside$14.00 Price TargetShort InterestHealthy5.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.42Based on 6 Articles This WeekInsider TradingSelling Shares$15,342 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector167th out of 1,009 stocksPharmaceutical Preparations Industry65th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Mersana Therapeutics has a forecasted upside of 95.5% from its current price of $7.16.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.67% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 11.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.5 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.Search Interest25 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 108% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,342.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions92.40% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($1.89) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 7.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mersana Therapeutics (NASDAQ:MRSN) StockMersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.Read More Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAnalysts Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $14.00May 29, 2023 | markets.businessinsider.comMersana Therapeutics (MRSN) Receives a Buy from SVB SecuritiesMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 28, 2023 | finance.yahoo.comThose who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127%May 19, 2023 | americanbankingnews.comTraders Buy High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)May 14, 2023 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Expected to Earn Q2 2023 Earnings of ($0.48) Per ShareMay 11, 2023 | msn.comCitigroup Maintains Mersana Therapeutics (MRSN) Buy RecommendationMay 11, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on Mersana Therapeutics (MRSN)May 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN), Twist Bioscience (TWST) and Beauty Health (SKIN)May 9, 2023 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsMay 8, 2023 | msn.comMersana Therapeutics Q1 2023 Earnings PreviewMay 8, 2023 | americanbankingnews.comBrokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $14.71May 7, 2023 | americanbankingnews.comMersana Therapeutics (MRSN) Set to Announce Quarterly Earnings on TuesdayMay 3, 2023 | finance.yahoo.comMersana Therapeutics to Present at Bank of America Securities 2023 Healthcare ConferenceMay 2, 2023 | finance.yahoo.comMersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023April 29, 2023 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal Sells 3,944 Shares of StockApril 28, 2023 | nasdaq.comUnusual Options Activity and Flow in Mersana Therapeutics (MRSN)April 19, 2023 | markets.businessinsider.comMersana Therapeutics (MRSN) Gets a Buy from BTIGApril 17, 2023 | finance.yahoo.comGetting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is UnlikelyApril 13, 2023 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $14.71 Average Price Target from AnalystsApril 11, 2023 | americanbankingnews.comPanbela Therapeutics (NASDAQ:PBLA) versus Mersana Therapeutics (NASDAQ:MRSN) Head to Head AnalysisApril 5, 2023 | finance.yahoo.comJ.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside PotentialApril 3, 2023 | seekingalpha.comMersana Therapeutics: Unrecognized Promise In UpRi's Cancer FightMarch 23, 2023 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Buy" by BrokeragesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Company Calendar Last Earnings5/09/2023Today5/30/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+84.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,210,000.00 Net Margins-658.85% Pretax Margin-658.85% Return on Equity-223.97% Return on Assets-71.17% Debt Debt-to-Equity Ratio0.39 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$26.58 million Price / Sales32.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book8.23Miscellaneous Outstanding Shares114,390,000Free Float109,353,000Market Cap$865.93 million OptionableNot Optionable Beta1.75 Key ExecutivesAnna ProtopapasPresident, Chief Executive Officer & DirectorBrian DeSchuytnerChief Financial Officer & Senior Vice PresidentTimothy B. LowingerChief Science & Technology OfficerArvin YangChief Medical Officer & Senior Vice PresidentAlejandra Veronica CarvajalSecretary, Chief Legal Officer & Senior VPKey CompetitorsMorphoSysNASDAQ:MORCymaBay TherapeuticsNASDAQ:CBAYANI PharmaceuticalsNASDAQ:ANIPPharming GroupNASDAQ:PHARAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,779 shares on 5/26/2023Ownership: 0.016%JPMorgan Chase & Co.Sold 265,258 shares on 5/18/2023Ownership: 0.106%New York State Common Retirement FundSold 18,873 shares on 5/18/2023Ownership: 0.032%Susquehanna International Group LLPBought 31,400 shares on 5/16/2023Ownership: 0.000%Sphera Funds Management LTD.Bought 10,621 shares on 5/16/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions MRSN Stock - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price forecast for 2023? 6 brokerages have issued 1-year price objectives for Mersana Therapeutics' stock. Their MRSN share price forecasts range from $10.00 to $20.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 84.9% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2023? Mersana Therapeutics' stock was trading at $5.86 at the beginning of 2023. Since then, MRSN stock has increased by 29.2% and is now trading at $7.57. View the best growth stocks for 2023 here. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.11. The company earned $7.80 million during the quarter, compared to analysts' expectations of $18.29 million. Mersana Therapeutics had a negative net margin of 658.85% and a negative trailing twelve-month return on equity of 223.97%. The business's quarterly revenue was up 290.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.59) EPS. What ETFs hold Mersana Therapeutics' stock? ETFs with the largest weight of Mersana Therapeutics (NASDAQ:MRSN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), State Street Corp (5.61%), Sarissa Capital Management LP (3.32%), Braidwell LP (2.93%), Candriam S.C.A. (2.72%) and Baker BROS. Advisors LP (1.65%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $7.57. How much money does Mersana Therapeutics make? Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $865.93 million and generates $26.58 million in revenue each year. The company earns $-204,210,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. How many employees does Mersana Therapeutics have? The company employs 169 workers across the globe. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com. This page (NASDAQ:MRSN) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.